Inomagen Therapeutics

Developing a novel Biological (Gene) Therapy to Improve the Treatment of Atrial Fibrillation

Inomagen Therapeutics is a private, preclinical-stage biotechnology company developing a non-viral gene therapy that targets the underlying mechanisms of Atrial Fibrillation. To achieve safe and effective gene delivery, the company is developing a novel, patented transcatheter gene delivery system.

About Inomagen

Atrial fibrillation is the most common sustained heart rhythm disorder and a growing epidemic in an aging population. Unfortunately, current therapies have proven ineffective for many patients as they do not address the underlying mechanisms of the disease.

At Inomagen, we are exclusively focused on discovering and developing transformative gene therapies to markedly improve the treatment of atrial fibrillation. Our scientific advancements have been the result of significant non-dilutive grant funding. The company has an exclusive license agreement with Northwestern University for a robust IP estate and has assembled a highly experienced team to bring our therapies to market.

Inomagen is located in Chicago’s Fulton Market as a portfolio member of Portal Innovations – a Biotech Incubator with an expansive space designed to provide best-in-class, fully equipped wet/dry lab and work space.

Meet the Team

Rishi Arora MD

FOUNDER & CEO

Dr. Arora is a well-published physician-scientist and a key thought leader in the area of atrial fibrillation. In addition to being a practicing electrophysiologist, Dr. Arora runs one of the busiest academic laboratories where he has raised over $20M in NIH grants for his work on AF therapies.
Gerard Abate MD

CHIEF MEDICAL OFFICER

Dr. Abate has a background as a clinical cardiologist and is well experienced in the healthcare industry. Over the past 30 years Dr. Abate has held numerous Pharma/Diagnostics leadership roles including Amarin Pharmaceuticals, Daiichi Sankyo, Atherotech, and as the Executive Director of Medical Affairs at Quest Diagnostics.
Eric Sandberg

CHIEF BUSINESS OFFICER

Eric has 30+ years of medical technology leadership experience at Guidant, Boston Scientific, Axogen and several start-up ventures, in roles that have included CEO, CBO, and CCO, and brings significant commercial experience in the cardiovascular space including cardiac rhythm management.
Scott Jordan

CHIEF FINANCIAL OFFICER
Robert Moen MD, PhD

SVP , SCIENCE AND MEDICAL AFFAIRS
David Johnson

LEAD ENGINEER
Robin Drassler

VP BUSINESS DEVELOPMENT
Jim Hausserman MD, MS

MANAGER, CLINICAL SCIENCE
Linda Su MA, MBA

PROJECT MANAGER, BUSINESS DEVELOPMENT